Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing a…
LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib…
TreatmentTrends: Multiple Sclerosis (US) is an annual syndicated report that provides a comprehensive view of the current and anticipated management of multiple sclerosis (MS) based on primary…
Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…
TreatmentTrends® are syndicated report series that provide information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of…
How Receptive Are Retinal Specialists and Payers to Emerging Therapies Offering Vision Improvements or Greater Dosing Convenience? Anti-vascular endothelial growth factor (VEGF) therapies…
How Receptive Are Retinal Specialists and Payers to Emerging Therapies Offering Vision Improvements or Greater Dosing Convenience? Anti-vascular endothelial growth factor (VEGF) therapies…
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
Methicillin-resistant Staphylococcus aureus (MRSA) is an important causative pathogen of a range of hospital-treated infections. The steadily increasing severity of infections caused by MRSA that…
Last Updated 13 December 2013 The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate…
Last Updated 9 December 2013 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. More patients…